immunosuppressive treatment and MCC onset is suggested. Indeed, MCC is associated with MCPyV LT oncoprotein activity.
Introduction
Merkel cell carcinoma (MCC) is a rare but aggressive neuroendocrine tumor (1).
Annual incidence is estimated at about 2.4-3/million/year in Europe (2) and the USA (3), respectively, with increased frequency over the last 20 years.
MCC arises more frequently in elderly people, white subjects of both genders, predominantly in sun-exposed areas, with the average onset age at presentation of 69 years old (4) . Its high mortality rate may be partially explained by the advanced onset age, which results in a decrease in immune function, closely related to aging (5) . Iatrogenic immunosuppression has been demonstrated to be a risk factor for MCC development:
immunosuppressed individuals, such as those affected by AIDS, oncologic or hematological diseases and organ transplant recipients (OTRs), represent approximately 10% of MCC affected patients (4) . These MCC immunosuppressed patients have poorer prognoses (6) . The role of immunosuppressive therapy in MCC pathogenesis is also suggested by reports of partial spontaneous regression of metastatic MCC after treatment discontinuation (7) .
DNA sequences of Merkel cell polyomavirus (MCPyV) were identified in MCC (8) .
Then, MCPyV sequences were detected in MCC in up to 80% of cases, whereas Ig antibodies against MCPyV were revealed in approximately 80% of healthy subjects and MCC affected patients. These results indicate that MCPyV, which is potentially oncogenic, is a ubiquitous human virus (9) .
The introduction of biologic disease modifying anti-rheumatic drugs (bDMARDs) in treating some rheumatic diseases, such as rheumatoid arthritis and spondyloarthritis, has completely changed the management and outcome of these disorders. Their efficacy has been widely demonstrated in several randomized clinical trials and observational registries. These
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Their safety profile has globally been demonstrated as satisfactory with a favorable risk/benefit ratio. However, more information about long term toxicity and harmfulness is necessary to assist clinicians in decision making and follow up. Some reviews have reported on this topic (10, 12) comparing the adverse events of tumor necrosis factor (TNF) blockers, interleukin (IL)-1 antagonist, IL-6 antagonist, anti-CD28 and anti-B cell monoclonal antibodies in the treatment of different rheumatic diseases. Overall, the difference between cancer rates was not statistically significant between patients treated with biologics and the control group not exposed to biologics, with conflicting results for non-melanoma skin cancer (NMSC). In UV exposed patients, a significantly increased risk of NMSC was reported by Wolfe and colleagues (13): (RR 1.5, 95% CI 1.2-1.8), in the ARTIS registry (14) , in particular in the first year of treatment (RR 2.1, 95% CI 0.8-5.1) and in recent systematic reviews and meta-analysis (12, 15) . Conversely, a non-significant increased risk was found in the CORRONA (http://www.rheumatology.org/; 1.83, 95% CI 0.85-3.93) and in the BSRBR registries (http://www.rheumatology.org.uk/; HR 1.7, 95% CI 0.9-3.4). Whereas, a study based on the BIOBADASER registry (16) failed to demonstrate an increased NMSC rate in the population treated with TNF inhibitor (TNFi). Previous skin cancer history, ethnic background and solar damage are some of the possible factors that could justify the difference in these results. Furthermore, a different risk profile for malignancies according to the specific autoimmune disease and the biologic drug employed in the treatment should be considered. The most common skin neoplasms related to anti-TNF therapy are basal and squamous cell carcinomas, while cutaneous lymphomas are rarely reported. However, some studies have described cases of patients with rheumatic disease treated with biologic drugs who have developed Merkel cell carcinoma (MCC) (16) (17) (18) .
Research. 
Materials and Methods

MCC cases
Three MCC cases, 2 in patients affected by rheumatoid arthritis and 1 in a patient with ankylosing spondylitis, all exposed to biologic drugs, mainly anti-TNF, were studied in detail 
MCC and PBMC DNA extraction
Total DNA was extracted from Merkel Cell Carcinoma (MCC), formalin fixed paraffin-embedded (FFPE) specimens, belonging to patients (n=3), using QIAmp DNA FFPE Tissue extraction Kit (Qiagen, Milan, Italy), as described (19) . Total DNA was extracted from PBMCs belonging to patients (n=3) using QIAmp DNA Blood Mini Kit (Qiagen, Milan, Italy), as described (20) . After DNA extraction, each sample was quantified by the spectrophotometric reading (NanoDrop 2000, Thermo Scientific, Milan, Italy). DNA was stored at -80°C until the time of the analysis. DNA was evaluated for its polymerase chain reaction (PCR) suitability by amplyfing the ß-globin gene sequences (21) .
MCPyV DNA detection and sequence analysis
In order to verify the presence of Merkel Cell Polyomavirus (MCPyV) DNA sequences, DNA from MCC and PBMC samples were analyzed by qualitative PCR with 
MCPyV DNA load quantification
Specific quantitative real-time PCR assays, using TaqMan chemistry, were performed using the CFX96 Touch™ Real-Time PCR Detection System (Biorad, Segrate, Milan, Italy)
for MCPyV DNA load quantification. Recombinant plasmid pMCPyVLT.1, which contains 258 bp of the large T antigen (24) coding sequence (FJ472933), was used as positive control (25) . Standard calibration curves were generated using 10-fold dilutions, from 10 1 to 10 7 copies, of pMCPyVLT.1 (20) . Cellular RNase P gene was used to determine the human cell equivalents of each sample under analysis (26) . Samples and controls were analyzed in
Research. (21) . FFPE slices, 4 µm thick, were stained with mouse monoclonal antibody against the MCPyV LT-antigen (CM2B4) (Santa Cruz Biotechnology, Santa Cruz, CA) (dilution, 1:50). Staining intensity and its distribution were assessed by the pathologists of our working group. Staining was graded as negative (no staining) and as weak, moderate, or strong intensity.
Detection of serum IgG antibodies against MCPyV VP1 protein and LT/ST antigens
Serum antibodies against MCPyV viral protein 1 (VP 1), large T and small t antigens (LT/ST) (27) , were detected by enzyme-linked immunosorbent assay (ELISA) using MCPyV virus-like particles (VLPs) and the recombinant LT/ST. VLPs and LT/ST were generated and purified as previously described (27, 28) . Detection of VP1 and LT/ST antibodies by indirect ELISA was performed as previously described (27, 28) .
Research. of PBMCs from healthy subjects (20) , whereas other groups found MCPyV sequences in PBMCs from MCC patients (32) . Herein, MCPyV DNA was detected in all 3 MCC samples, while none of the 3 PBMCs analyzed showed MCPyV DNA sequences ( Table 1) .
The viral DNA load from the three MCPyV-positive MCC samples was evaluated by specific real-time quantitative PCR (qPCR) analysis (Table 2 ). In the MCC sample from patient 1, the mean MCPyV DNA load was 29.89 copy/cell (range: 18.27 copy/cell to 42.68 copy/cell). In the MCC sample from patient 2, the mean MCPyV DNA load was 0.1 copy/cell (range: 0.05 copy/cell to 0.15 copy/cell). In the MCC sample from patient 3, the mean MCPyV DNA load was 1.5 copy/cell (range: 0.7 copy/cell to 2.37 copy/cell), (Table 2) .
In order to check PCR amplicons specificity as obtained in the three MCC samples from patients, the amplified products were subjected to DNA sequencing (Fig. 1) . DNA sequence data were compared to the reference sequence, shown in Fig. 1, A, 
MCPyV LT-antigen analysis by IHC staining
In order to evaluate MCPyV LT-antigen protein expression, IHC staining on MCC tissue samples from patients (n=3) was carried out. MCPyV LT-antigen staining was present in all tissue sections. Specifically, MCPyV LT-antigen was strongly expressed with diffuse nuclear localization (Fig.2 , panels A-C) in MCC tissue samples from patients. In the corresponding normal tissues, MCPyV LT-antigen expression was not detected (Fig. 2, panel   D ).
MCPyV antibodies detection by indirect ELISA
Indirect ELISA was carried out in order to determine the presence of serum antibodies against MCPyV in MCC patients. Sera from the three patients, who were found to be 
Discussion
In this report, we characterized 3 new MCC cases in patients affected by rheumatologic diseases, all of whom had been exposed to biologic drugs, where a possible cause-effect relationship between the pharmacological immunosuppressive treatment and cancer arisen could be hypothesized. It has been established that, MCC onset/progression is linked to MCPyV and viral LT gene expression promotes tumor onset/progression (8, 29) .
In this study, MCPyV LT DNA sequences were detected in all three MCC samples.
Our results are in agreement with previous works where approximately 80% of MCCs are associated with MCPyV (8, 29) , suggesting that this virus is likely to be the etiology agent of MCC (8, 29) . We detected a viral DNA copy/cell ratio within a 0.06-1.2 range, which is sufficient to contribute to MCC (30) . Molecular analysis of MCPyV LT DNA sequences from the three cases showed high homology with previously published MCPyV sequences obtained from MCC specimens. Specifically, we identified the MKL-1 strain, suggesting that this strain is the main MPCyV isolate in Europe (20, 31) . Strong MCPyV LT antigen (LTA) expression in immunohistochemistry, with diffuse nuclear localization, was evaluated in the three MCC tissues. These findings support the thesis that MCPyV has an essential role in MCC-genesis (30) . It is interesting to note that the corresponding PBMCs from the same patients tested negative for MCPyV DNA. In this context, it should be recalled that MCPyV DNA in PBMCs, when revealed, is present at low copy number in patients affected by MCC (32) , as well as in healthy subjects (20) .
We investigated the presence of serum antibodies against MCPyV in samples of the same three MCC patients. Anti-MCPyV VP1 antibodies were detected in all three patients, whereas anti-MCPyV LT/ST antibodies were detected in patients 1 and 3. It could be speculated that the absence of LT/ST antibodies in patient 2 is due to the small tumor size. In our case, the lag time between initial exposure to a biologic (anti-TNF in all case) and MCC occurrence was rather wide, ranging from 23 to 60 months, compared to the 18-24 months reported by others (16) (17) (18) . Advanced age in patients affected by MCC has been reported as a risk factor for the onset/progression of this tumor (4) . Indeed, in our study, patients 1 and 3 were 70 years old and patient 2 was 56 years old. Previously, the highest incidence of MCC had been observed in people above 65 years of age (3). However, in previous reports of patients affected by rheumatic diseases in whom an MCC did occur after exposition to anti-TNF, only 1 out of 3, was over 70 (16) (17) (18) . Nevertheless, advanced age combined with impaired immune function in the elderly seems to be an important risk factor for MCPyV-related MCC (39) .
Conclusion
In conclusion, immunosuppression due to biologic drug therapies, chiefly anti-TNF, could represent a risk factor for MCC development in rheumatic patients. Our study data, 
